When Investigating Fluoroquinolone Reactions, Move beyond the ER

Hormones Matter Logo

If you’re looking at the number of trips to the ER that result from fluoroquinolones in order to determine how safe they are, YOU’RE LOOKING AT THE WRONG DATA POINT!  Here is an essay about the topic of ER visits and how they relate to determining the safety of fluoroquinolones.

http://www.hormonesmatter.com/fluoroquinolone-reactions-beyond-er/

As always, thank you for reading it!

flu tox get help you need banner click lisa

Tagged: , , , , , ,

3 thoughts on “When Investigating Fluoroquinolone Reactions, Move beyond the ER

  1. CATHY POGORZELSKI December 12, 2013 at 2:07 pm Reply

    Lisa: Medicine has been master manipulators of the truth and good science when
    as you stated:

    Asking the wrong question and expecting the right answer has never served anyone well, and doing that systematically in medicine is not serving patients or doctors well. It is not good for healthcare and it is not good for anyone seeking the truth about adverse drug reactions.

    Please, see the links contained in this post and make no wonder as to IF IT IS DONE and let’s try to concentrate on WHY?! Many of the drugs now in use are GOING TO BE FOUND OUT as the frauds they truly are, MRI contrast Gadolinium being on the forefront; as to why it was EVER approved by the FDA, is beyond me!
    this article, shows that one lone, dissenting voice of Dr Mark Greene, The way this molecule was created, it is very similar to the other agents already on the market,” Lily Jung Henson, MD, committee member and acting consumer representative told Medscape Medical News. “We felt the risk benefit profile was very much like the other products.” Dr. Jung Henson is based at the Swedish Neuroscience Institute in Seattle, Washington.

    Committee member Mark Green, MD, from the Mount Sinai School of Medicine in New York voiced concern about postmarketing data. He emphasized the importance of continued vigilance and monitoring for adverse events. Committee member Mark Green, MD, from the Mount Sinai School of Medicine in New

    I had my 7th & 8th biopsies done at Mt Sinai, by Noah Scheinfeld an earl researcher into NSF, what pisses me off is he STILL would NTO dx a”NON-Nephrogenic Systemic Fibrosis” as they are all in it for the money. I fI prove cause and effect, esssentially EVERY SINGLE IMAGING CENTER WOULD HAVE TO RID THEMSELVES OF GADOLINIUM CONTRAST, as the biggest FRAUD foist upon the world! YEs, Take a really pretty picture, AT WHAT COST?! In my opinion, GAD is the THOROTRAST OF THE ’80’s & beyond, opening the way of patients with “FIBROMYALGIA” instead of what it truly is “FIBROSIS!” ( in those having had MRI contrast)
    LET’S see what the medical community has in store next.

    here they are figuring ways of giving EOVIST, a gadolinium containing contrast, to OBESE patients:
    http://www.auntminnie.com/index.aspx?sec=eba&sub=eml&pag=dis&itemId=105982&wf=5746

    Indications and Usage

    Eovist® (gadoxetate disodium) injection is a gadolinium-based contrast agent indicated for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

    Important Safety Information

    WARNING: NEPHROGENIC
    SYSTEMIC FIBROSIS (NSF)

    Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.
    • The risk for NSF appears highest among patients with:
    — Chronic, severe kidney disease
    (GFR 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

    • For patients at highest risk for NSF, do not exceed the recommended Eovist dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration
    (see Warnings and Precautions).

    REMEMBER I DID NOT HAVE ANY KIDNEY DISEASE “PRIOR” TO THE MRI’S AND IF THEY MISSED TAHT I DID OR CUSED IT THEY ARE SCREWED EITHER WAY!!!
    Contraindication and Important Information about Hypersensitivity Reactions:
    Eovist is contraindicated in patients with history of severe hypersensitivity reactions to Eovist. Anaphylactoid and anaphylactic reactions with cardiovascular, respiratory and cutaneous manifestations, ranging from mild to severe reactions, including shock have uncommonly occurred following Eovist administration. Patients with any history of a reaction to contrast media, bronchial asthma, and/or allergic disorders may have an increased risk for a hypersensitivity reaction to Eovist.

    Acute Kidney Injury: In patients with chronic renal impairment, acute kidney injury sometimes requiring dialysis has been observed with the use of some GBCAs. The risk of acute kidney injury might be lower with Eovist due to its dual excretory pathways. Do not exceed the recommended dose.

    Extravasation and Injection Site Reactions:Ensure catheter and venous patency before the injection of Eovist. Extravasation into tissues during Eovist administration may result in local tissue reactions. Strictly avoid intramuscular administration of Eovist because it may cause myocyte necrosis and inflammation.

    Interference with Laboratory Tests: Serum iron determination using complexometric method (for example, Ferrocine complexation method) may result in falsely high or low values for up to 24 hours after Eovist administration.

    Interference with Visualization of Liver Lesions: Severe renal or hepatic failure may impair Eovist imaging performance. In patients with end-stage renal failure, hepatic contrast was markedly reduced and attributed to elevated serum ferritin levels. In patients with abnormally high (>3 mg/dL) serum bilirubin, reduced hepatic contrast was observed. If Eovist is used in these patients, complete MR imaging no later than 60 minutes after Eovist administration and use a paired non-contrast and contrast MRI set for diagnosis.

    Adverse Reactions: The most frequent (≥0.5%) adverse reactions associated with Eovist are nausea (1.1%), headache (1.1%), feeling hot (0.8%), dizziness (0.6%), and back pain (0.6).

    Please see full prescribing information

    Expanded Contrast Delivery
    and Dosing Options

    Eovist 15mL single-dose vial is
    available to conveniently dose
    patients weighing 220-330 lbs

    SEE MORE WITH EOVIST ®

    As compared to pre-contrast MRI:

    Significant improvement in detection of metastases and hepatocellular carcinomas1

    12% more small metastases (<1 cm in diameter) detected*1

    High confidence of lesion characterization 92% versus 63%2

    EOVIST allows for greater detection of malignant lesions with high confidence as compared to pre-contrast¹

    *Standard of reference (SOR): surgical specimen and/or
    intraoperative US (IOUS).
    I WAS GIVEN 10 MLs every MRI w/contrast (7 of them in about 10-15 yrs time that I can count!!) I weighed 92 lbs for most of them!!
    Cathy

  2. Lisa Bloomquist December 14, 2013 at 3:18 pm Reply

    Catherine – Thank you very much for the information and for your passion! You are fighting hard and I appreciate all the time, effort, energy, etc. that you put into fighting. It’s a good fight that’s worth the effort.

    Lisa

  3. CATHY POGORZELSKI December 14, 2013 at 9:10 pm Reply

    You have been very busy yourself on the FQ front, we will have to hit them at every angle to get somewhere. I once had a urologist tell me, ” what you have is something going on in the connective tissue realm and you WILL NEED GOOD GENERAL IN YOUR CORNER DIRECTING THE TROOPS!” That urologist has died suddenly in his early 60’s at 5′ & 3/4″, my husband calls my fighting spirit, “my Napolean Complex!” Despite what happened to him, may he always guide me…

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: